Project Details
Description
A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
| Status | Finished |
|---|---|
| Effective start/end date | 2/1/17 → 3/28/22 |
Funding
- IGNYTA, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.